Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript May 7, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 17,100 | $905,787 | 0.01% | |
| 2. | BIT Capital GmbH Jan Beckers | 6,013 | $318,509 | 0.03% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 3,134 | $119,924 | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | Officer, Director | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | Director | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | Large Shareholder | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | Large Shareholder, Director | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | Large Shareholder | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $65.09 | 7,031 | Officer | 19,209 | 2025-04-29 | Filing | |
| $65.08 | 6,745 | Officer | 37,655 | 2025-04-29 | Filing | |
| $62.00 | 7,030 | Officer | 19,209 | 2025-04-08 | Filing | |
| $60.00 | 6,700 | Officer | 26,239 | 2025-04-08 | Filing | |
| $59.00 | 600 | Officer | 32,939 | 2025-04-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,854,755 | $363,096,374 | 0.01% | |
| 2. | 5,787,322 | $306,554,446 | 0.25% | |
| 3. | 3,444,926 | $182,477,729 | 0% | |
| 4. | 1,637,908 | $86,759,987 | 0.01% | |
| 5. | 1,591,871 | $84,321,407 | 0.18% |
News See All
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript February 26, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
14 Worst 52-Week High Stocks to Buy According to Short Sellers
The start of the US Federal Reserve cutting cycle ushers a new era in the investment world after one of the longest bull runs.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc.
Jim Cramer Portfolio: 11 Latest Stocks to Buy
In this article, we will take a detailed look at Jim Cramer Portfolio: 11 Latest Stocks to Buy.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.7 EPS, expectations were $-0.7. Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.